Definitive Healthcare (NASDAQ:DH) Given New $3.00 Price Target at Barclays

Definitive Healthcare (NASDAQ:DH) had its price target cut by Barclays from $4.00 to $3.00 in a research report sent to investors on Monday,Benzinga reports. They currently have an underweight rating on the stock.

A number of other research analysts also recently weighed in on the company. Stephens assumed coverage on Definitive Healthcare in a report on Friday, December 20th. They set an “equal weight” rating and a $5.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Definitive Healthcare currently has a consensus rating of “Hold” and an average price target of $5.35.

Definitive Healthcare Stock Down 0.4 %

Shares of Definitive Healthcare stock opened at $2.77 on Monday. The stock’s fifty day moving average is $4.55 and its 200-day moving average is $4.45. The firm has a market capitalization of $320.00 million, a PE ratio of -0.89, a price-to-earnings-growth ratio of 4.06 and a beta of 1.45. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. Definitive Healthcare has a 12-month low of $2.58 and a 12-month high of $8.71.

Definitive Healthcare (NASDAQ:DH) last announced its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.04). The company had revenue of $62.29 million for the quarter, compared to analyst estimates of $60.60 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. Equities analysts anticipate that Definitive Healthcare will post 0.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its stake in shares of Definitive Healthcare by 3,652.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,980 shares of the company’s stock worth $29,000 after acquiring an additional 6,794 shares in the last quarter. Bayesian Capital Management LP bought a new stake in shares of Definitive Healthcare during the 4th quarter worth about $41,000. Point72 DIFC Ltd lifted its position in shares of Definitive Healthcare by 759.9% during the 3rd quarter. Point72 DIFC Ltd now owns 9,296 shares of the company’s stock worth $42,000 after purchasing an additional 8,215 shares during the last quarter. Ieq Capital LLC acquired a new position in shares of Definitive Healthcare during the 4th quarter worth about $51,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Definitive Healthcare during the 4th quarter worth about $54,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.